Interactive Updates in Solid Tumor Cancers: Melanoma Module
In 2013, the American Cancer Society (ACS) named lung
cancer, colorectal cancer, and melanoma in their list of topten new cancer cases.
The ACS estimates that within the year, there will be 118,080 new cases of lung cancer in men and 110,110 new cases in women; 73.680 new cases of colorectal cancer in men and 69,140 new cases in women; and 45,060 new cases of melanoma in men and 31,630 new cases in women.
Together, these cancers will account for 28% of new cancer cases in American men and 27% in American women in 2013.*
In recent years, significant clinical advancements have been made in each of these disease areas: the impact of effective
screening methods has been discussed, the role of biomarkers and gene profiling investigated, and the possibility
of novel therapies evaluated. It is critical for oncologists and healthcare professionals involved in the treatment of lung
cancer, colorectal cancer, and melanoma to stay up-to-date on these developments so they can be equipped to provide
the best treatment for their cancer patients.
* American Cancer Society. Cancer Facts & Figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. 2013.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Genentech Inc. and Merck & Co.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Medical College of Wisconsin, Carden Jennings Publishing, Genentech, Inc., or Merck & Co.
Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
This program has been designed for a targeted audience of medical oncologists and radiation oncologists who have an interest in malignant melanoma.
Upon completion of the program, participants should be
1. Describe recent data supporting malignant melanoma screening and educational efforts
2. Compare existing and emerging immunotherapeutic treatment options for patients based on evidencebased data
3. Employ appropriate clinical strategies for prevention and management of adverse events and toxicities typically associated with immunotherapy in the treatment of malignant melanoma
4. Evaluate the data presented regarding treatment options, including surgical management, for malignant melanoma in their clinical practice to effectively improve patient outcomes
Howard L. Kaufman, MD, FACS completed medical school at Loyola University in Chicago, surgical residency at Boston University and fellowship training in Tumor Immunology and Surgical Oncology, both at the National Cancer Institute in Bethesda, Maryland. Dr. Kaufman is a Fellow of the American College of Surgeons and his clinical interests focus on melanoma and his research interests include oncolytic viruses and tumor immunotherapy. Dr. Kaufman has conducted numerous clinical trials and chaired several multi-institutional and cooperative group clinical studies. He serves on several editorial boards and has authored or coauthored over 200 peer-reviewed manuscripts, books, book chapters, review articles and abstracts. He is the author of The Melanoma Book, published by Gotham Books as a comprehensive educational resource for patients with melanoma. He has received numerous awards for his scientific research and has been named as one of the best doctors in the United States by Castle-Connolly. Dr. Kaufman is a member of many national and international scientific societies and serves as a consultant to the National Cancer Institute and several
pharmaceutical and biotechnology companies. He was appointed to the Board of Directors of the Society for the Immunotherapy of Cancer and is currently serving as Vice President of the Melanoma Research Foundation, and as a member of the Society for Melanoma Research and the Board of Visitors of the University of Illinois at Chicago. Dr. Kaufman has held several academic appointments, including the Weiskopf Endowed Chair at Columbia University in New York City and served as Associate Dean and Director of the Rush University Cancer Center in Chicago. In January 2014 he will become the Chief Surgical Officer and Associate Director for Clinical Sciences at the Rutgers Cancer Institute of New Jersey.
Howard L. Kaufman, MD, FACS discloses that he is a consultant for Amgen, Merck & Co., and Prometheus Laboratories.
Howard L. Kaufman, MD
Associate Director for Clinical Sciences
Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901
732-235-2465; Fax :732-235-6797
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.